IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 19.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,933 shares of the company’s stock after selling 1,229 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in IDEXX Laboratories were worth $2,039,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Venturi Wealth Management LLC grew its holdings in shares of IDEXX Laboratories by 465.3% during the 4th quarter. Venturi Wealth Management LLC now owns 571 shares of the company’s stock worth $236,000 after purchasing an additional 470 shares during the period. D.A. Davidson & CO. grew its holdings in shares of IDEXX Laboratories by 2.8% during the 4th quarter. D.A. Davidson & CO. now owns 1,674 shares of the company’s stock worth $692,000 after purchasing an additional 45 shares during the period. Truist Financial Corp grew its holdings in shares of IDEXX Laboratories by 13.9% during the 4th quarter. Truist Financial Corp now owns 27,784 shares of the company’s stock worth $11,487,000 after purchasing an additional 3,382 shares during the period. CIBC Asset Management Inc grew its holdings in shares of IDEXX Laboratories by 3.1% during the 4th quarter. CIBC Asset Management Inc now owns 26,366 shares of the company’s stock worth $10,901,000 after purchasing an additional 788 shares during the period. Finally, J.W. Cole Advisors Inc. grew its holdings in shares of IDEXX Laboratories by 4.5% during the 4th quarter. J.W. Cole Advisors Inc. now owns 2,760 shares of the company’s stock worth $1,141,000 after purchasing an additional 118 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $452.77 on Friday. The stock has a market cap of $37.08 billion, a P/E ratio of 42.43, a price-to-earnings-growth ratio of 3.41 and a beta of 1.37. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The stock has a 50 day moving average of $431.92 and a 200-day moving average of $452.40. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39.

Analyst Ratings Changes

A number of equities analysts have weighed in on IDXX shares. Leerink Partners started coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target for the company. Barclays upped their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Morgan Stanley decreased their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Finally, Bank of America upped their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average target price of $533.75.

Insider Activity

In related news, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Sophie V. Vandebroek sold 344 shares of the company’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the sale, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. This represents a 27.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 13,330 shares of company stock worth $6,161,276. 2.11% of the stock is currently owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.